171 related articles for article (PubMed ID: 25092334)
1. Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.
Hemmerle T; Doll F; Neri D
Proc Natl Acad Sci U S A; 2014 Aug; 111(33):12008-12. PubMed ID: 25092334
[TBL] [Abstract][Full Text] [Related]
2. Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis.
Schmid AS; Hemmerle T; Pretto F; Kipar A; Neri D
Rheumatology (Oxford); 2018 Apr; 57(4):748-755. PubMed ID: 29365185
[TBL] [Abstract][Full Text] [Related]
3. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
4. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.
Doll F; Schwager K; Hemmerle T; Neri D
Arthritis Res Ther; 2013 Sep; 15(5):R138. PubMed ID: 24289726
[TBL] [Abstract][Full Text] [Related]
5. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation.
Hemmerle T; Zgraggen S; Matasci M; Halin C; Detmar M; Neri D
J Dermatol Sci; 2014 Nov; 76(2):96-103. PubMed ID: 25190364
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.
Schwager K; Kaspar M; Bootz F; Marcolongo R; Paresce E; Neri D; Trachsel E
Arthritis Res Ther; 2009; 11(5):R142. PubMed ID: 19781067
[TBL] [Abstract][Full Text] [Related]
7. Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.
Schmid AS; Tintor D; Neri D
J Biotechnol; 2018 Apr; 271():29-36. PubMed ID: 29438784
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
9. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
10. Targeted IL-4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis.
Kawalkowska JZ; Hemmerle T; Pretto F; Matasci M; Neri D; Williams RO
Eur J Immunol; 2016 May; 46(5):1246-57. PubMed ID: 26919786
[TBL] [Abstract][Full Text] [Related]
11. The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.
Quattrone F; Sanchez AM; Pannese M; Hemmerle T; Viganò P; Candiani M; Petraglia F; Neri D; Panina-Bordignon P
Reprod Sci; 2015 Sep; 22(9):1143-52. PubMed ID: 25850899
[TBL] [Abstract][Full Text] [Related]
12. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
13. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
14. Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis.
Gouyou B; Ongaro T; Cazzamalli S; De Luca R; Kerschenmeyer A; Valet P; Villa A; Neri D; Matasci M
Exp Biol Med (Maywood); 2021 Apr; 246(8):940-951. PubMed ID: 33475433
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
16. IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10.
Steen-Louws C; Hartgring SAY; Popov-Celeketic J; Lopes AP; de Smet MBM; Eijkelkamp N; Lafeber FPJG; Hack CE; van Roon JAG
Clin Exp Immunol; 2019 Jan; 195(1):1-9. PubMed ID: 30307604
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.
Ziffels B; Grötsch A; Al-Bayati L; Neri D
J Biotechnol; 2019 Jan; 290():53-58. PubMed ID: 30579890
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
19. Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.
Bootz F; Schmid AS; Neri D
Inflamm Bowel Dis; 2015 Aug; 21(8):1908-17. PubMed ID: 25993691
[TBL] [Abstract][Full Text] [Related]
20. Targeting interleukin-4 to the arthritic joint.
Spieler V; Ludwig MG; Dawson J; Tigani B; Littlewood-Evans A; Safina C; Ebersbach H; Seuwen K; Raschig M; Ter Mors B; Müller TD; Meinel L; Lühmann T
J Control Release; 2020 Oct; 326():172-180. PubMed ID: 32653504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
